Study summary · research use only
Humanin Ameliorates Free Fatty Acid-Induced Endothelial Inflammation by Suppressing the NLRP3 Inflammasome
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used human aortic endothelial cells (HAECs) to examine whether the mitochondrial-derived peptide humanin affects free-fatty-acid-induced endothelial injury via the NLRP3 inflammasome. The abstract reports that humanin treatment reduced free-fatty-acid-induced lactate dehydrogenase release, lowered markers of oxidative stress including reactive oxygen species and NOX2 expression, reduced NLRP3 and p10 levels, altered free-fatty-acid-induced changes in AMP-activated protein kinase activity, and lowered expression of IL-1β and IL-18. The authors describe humanin as a candidate therapeutic agent for cardiovascular disease based on these cell culture findings.
Abstract
Cardiovascular disease (CVD) has been considered as a major risk factor of death in recent decades. In CVDs, the NLRP3 inflammasome is important for inflammatory response and vascular damage. Therefore, safe and effective treatments to decrease NLRP3 inflammasome activation are required. Increased levels of free fatty acid (FFA) have been associated with the progression of CVD. Humanin, a kind of mitochondrial-derived peptide, has shown its beneficial effects in different types of cells. However, the roles of humanin in the NLRP3 inflammasome induced by FFA are still unknown. Here, we investigated the molecular mechanisms whereby humanin was found to exert protective effects in human aortic endothelial cells (HAECs) against FFA-caused endothelial injury. Here, treatment with humanin inhibited FFA-induced lactate dehydrogenase release, thereby demonstrating a protective capacity against cell death. Humanin also suppressed oxidative stress by downregulating the expression of reactive oxygen species and NOX2. Notably, humanin reduced NLRP3 and p10 and rescued FFA-induced dysfunction of adenosine monophosphate-activated protein kinase. Consequently, humanin inhibited the expression of IL-1β and IL-18. These results conclude that humanin might be a promising therapeutic agent for CVD.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.